Novartis is pushing deeper into antibody-drug conjugate (ADC) development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload. Switzerland’s Novartis largely stayed ...
In the wake of a recent safety scare in a confirmatory trial of its antibody-drug conjugate Zynlonta, ADC Therapeutics is tightening its belt in an effort to get the most out of its cancer med. On ...
In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a ...
Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions about the antibody-drug conjugate (ADC), which has been on the market ...
CHICAGO -- Treatment with investigational izalontamab brengitecan (iza-bren) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with unresectable locally ...
It’s been three-and-a-half years since generative AI exploded onto the scene. In this past year, progress has continued its relentless pace: Vibe coding took off, companies embraced agentic workflows, ...
Development and evaluation of a novel digital pathology image analysis pipeline for prediction of clinical outcomes with the TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan ...
Antibody-drug conjugates (ADCs) have emerged as one of the most impactful therapeutic advances in modern oncology, fundamentally reshaping the treatment landscape across both hematologic malignancies ...
As I sat on the bow of a sailboat, marveling at the turquoise waters below and cave-strewn shores ahead, the sun trickled over my bare shoulders and a salty breeze swept through my hair. I reached for ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with type 2 diabetes who use GLP-1 analogs ...
ADCs have transformed metastatic breast cancer care. How do you see their role evolving in earlier-stage TNBC and HR+ breast cancer? ADCs have been remarkably effective therapies and are moving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results